Generalized MG (gMG) is a common form of MG. It is a rare autoimmune neuromuscular disease characterized by fluctuating muscle weakness.4,5
Symptoms can go beyond the physical—with potential for mental, emotional, and social impacts on patients’ lives.1,2,6
Managing symptoms and minimizing impact of symptoms are important goals for patients.3
Take another PASS
To uncover the impact of recurring symptoms on patients with gMG, ask:
Considering all the ways you are affected by [gMG], if you had to stay in your current state for the next months, would you say that your current disease state status is satisfactory?7,8
The Patient Acceptable Symptom State (PASS) evaluation is a single-question score that has been validated in several chronic inflammatory diseases.7,8
References: 1. Law N, Davio K, Blunck M, et al. The lived experience of myasthenia gravis: a patient-led analysis. Neurol Ther. 2021;10(2):1103-1125. doi:10.1007/s40120-021-00285-w 2. Pesa J, Choudhry Z, de Courcy J, et al. The impact of myasthenia gravis severity on work and daily activities. Muscle Nerve. 2024;69(4):428-439. doi:10.1002/mus.28063 3. Jackson K, Parthan A, Lauher-Charest M, et al. Understanding the symptom burden and impact of myasthenia gravis from the patient's perspective: a qualitative study. Neurol Ther. 2023;12(1):107-128. 4. Gilhus NE, Tzartos S, Evoli A, et al. Myasthenia gravis. Nat Rev Dis Primer. 2019;5(30):1-19. doi.org/10.1038/s41572-019-0079-y 5. Ye Y, Murdock DJ, Chen C, et al. Epidemiology of myasthenia gravis in the United States. Front Neurol. 2024;15:1-10. doi.org/10.3389/fneur.2024.1339167 6. Saccà F, Salort-Campana E, Jacob S, et al. Refocusing generalized myasthenia gravis: patient burden, disease profiles, and the role of evolving therapy. Eur J Neurol. 2024;31(6):e16180. doi:10.1111/ene.16180. Epub 2023 Dec 20 7. Mendoza M, Tran C, Bril V, et al. Patient-acceptable symptom states in myasthenia gravis. Neurology. 2020;95:1617-1628. doi:10.1212/WNL.0000000000010574 8. Petersson M, Feresiadou A, Jons D, et al. Patient-reported symptom severity in a nationwide myasthenia gravis cohort: cross-sectional analysis of the Swedish GEMG study. Neurol. 2021;97:1382-1391. doi:10.1212/WNL.0000000000012604